Menopausal Symptoms Cooled By KaNDy's Dual Neurokinin Antagonist
Faster relief of debilitating menopausal symptoms in early-stage clinical trial results suggest a potential new class of products being evaluated by UK biotech KaNDy Therapeutics may be useful against the condition.
You may also be interested in...
Armed with a fresh injection of £25m, the UK's KaNDy is about to begin Phase IIb trials of a dual mechanism therapy it believes will be a transformational treatment to tackle two key symptoms of the menopause, hot flashes and night time awakenings.
Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.
Astellas is looking to cut hundreds of positions in Japan as it faces a major upcoming patent expiry and refocuses under a new strategic plan.